Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
Medicine
|
August 28, 2020
Red cell distribution width to platelet ratio predicts liver fibrosis in patients with autoimmune hepatitis
Huali Wang, Jian Wang, Juan Xia, et al.
Biochemical Pharmacology
|
January 30, 2026
MICALL2 promotes angiogenesis of colorectal cancer by regulating the EGFR/PI3K/AKT/KLF5/VEGFA axis
Shuzhen Hu, Fan Wang, Jiamei Xu, et al.
Journal of Clinical and Translational Hepatology
|
July 5, 2021
Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
Wei Zhang, Lu Liu, Ming Zhang, et al.
International Journal of Obesity (2005)
|
July 4, 2026
A novel berberine derivative B12 exhibits superior anti-obesity effects via targeting brown and white adipocyte dynamics
Wenqing Zhang, Yanhong Feng, Chunyi Gao, et al.
Fertility and Sterility
|
June 25, 2021
Circulating fibroblast growth factor 21 as a potential biomarker for missed abortion in humans
Yongkang Yang, Jiaming Wu, Xia Wang, et al.
Med (New York, N.Y.)
|
July 1, 2026
AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies
Lin Lv, Chang Liu, Lidan Hu, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development
Jeffrey M Axten, Stuart P Romeril, Arthur Shu, et al.
Journal of Medicinal Chemistry
|
July 26, 2012
Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)
Jeffrey M Axten, Jesús R Medina, Yanhong Feng, et al.
Journal of Medicinal Chemistry
|
February 24, 2011
Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors
Jesús R Medina, Christopher J Becker, Charles W Blackledge, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
Medicine
|
August 28, 2020
Red cell distribution width to platelet ratio predicts liver fibrosis in patients with autoimmune hepatitis
Huali Wang, Jian Wang, Juan Xia, et al.
Biochemical Pharmacology
|
January 30, 2026
MICALL2 promotes angiogenesis of colorectal cancer by regulating the EGFR/PI3K/AKT/KLF5/VEGFA axis
Shuzhen Hu, Fan Wang, Jiamei Xu, et al.
Journal of Clinical and Translational Hepatology
|
July 5, 2021
Validation of the Nanjing Criteria for Diagnosing Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstruction Syndrome
Wei Zhang, Lu Liu, Ming Zhang, et al.
International Journal of Obesity (2005)
|
July 4, 2026
A novel berberine derivative B12 exhibits superior anti-obesity effects via targeting brown and white adipocyte dynamics
Wenqing Zhang, Yanhong Feng, Chunyi Gao, et al.
Fertility and Sterility
|
June 25, 2021
Circulating fibroblast growth factor 21 as a potential biomarker for missed abortion in humans
Yongkang Yang, Jiaming Wu, Xia Wang, et al.
Med (New York, N.Y.)
|
July 1, 2026
AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies
Lin Lv, Chang Liu, Lidan Hu, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development
Jeffrey M Axten, Stuart P Romeril, Arthur Shu, et al.
Journal of Medicinal Chemistry
|
July 26, 2012
Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)
Jeffrey M Axten, Jesús R Medina, Yanhong Feng, et al.
Journal of Medicinal Chemistry
|
February 24, 2011
Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors
Jesús R Medina, Christopher J Becker, Charles W Blackledge, et al.
Page
of 7